Global Drugs for Irritable Bowel Syndrome Market 2023 by Company, Regions, Type and Application, Forecast to 2029
According to our (Global Info Research) latest study, the global Drugs for Irritable Bowel Syndrome market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report is a detailed and comprehensive analysis for global Drugs for Irritable Bowel Syndrome market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Drugs for Irritable Bowel Syndrome market size and forecasts, in consumption value ($ Million), 2018-2029
Global Drugs for Irritable Bowel Syndrome market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Drugs for Irritable Bowel Syndrome market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Drugs for Irritable Bowel Syndrome market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Drugs for Irritable Bowel Syndrome
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Drugs for Irritable Bowel Syndrome market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Takeda Pharmaceutical Company Limited, Pfizer, Inc., Abbott Laboratories, Novartis AG and AstraZeneca PLC, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Drugs for Irritable Bowel Syndrome market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chapter 1, to describe Drugs for Irritable Bowel Syndrome product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Drugs for Irritable Bowel Syndrome, with revenue, gross margin and global market share of Drugs for Irritable Bowel Syndrome from 2018 to 2023.
Chapter 3, the Drugs for Irritable Bowel Syndrome competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Drugs for Irritable Bowel Syndrome market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Drugs for Irritable Bowel Syndrome.
Chapter 13, to describe Drugs for Irritable Bowel Syndrome research findings and conclusion.
This report is a detailed and comprehensive analysis for global Drugs for Irritable Bowel Syndrome market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Drugs for Irritable Bowel Syndrome market size and forecasts, in consumption value ($ Million), 2018-2029
Global Drugs for Irritable Bowel Syndrome market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Drugs for Irritable Bowel Syndrome market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Drugs for Irritable Bowel Syndrome market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Drugs for Irritable Bowel Syndrome
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Drugs for Irritable Bowel Syndrome market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Takeda Pharmaceutical Company Limited, Pfizer, Inc., Abbott Laboratories, Novartis AG and AstraZeneca PLC, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Drugs for Irritable Bowel Syndrome market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Alosetron
- Lubiprostone
- Linaclotide
- Others
- Hospital
- Clinic
- Others
- Takeda Pharmaceutical Company Limited
- Pfizer, Inc.
- Abbott Laboratories
- Novartis AG
- AstraZeneca PLC
- Ironwood Pharmaceuticals Inc. and Allergan Plc
- Bausch Health Companies Inc.
- GlaxoSmithKline, Plc.
- Lexicon Pharmaceuticals, Inc.
- Sucampo Pharmaceuticals, Inc.
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
- South America (Brazil, Argentina and Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe Drugs for Irritable Bowel Syndrome product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Drugs for Irritable Bowel Syndrome, with revenue, gross margin and global market share of Drugs for Irritable Bowel Syndrome from 2018 to 2023.
Chapter 3, the Drugs for Irritable Bowel Syndrome competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Drugs for Irritable Bowel Syndrome market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Drugs for Irritable Bowel Syndrome.
Chapter 13, to describe Drugs for Irritable Bowel Syndrome research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Drugs for Irritable Bowel Syndrome
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Drugs for Irritable Bowel Syndrome by Type
1.3.1 Overview: Global Drugs for Irritable Bowel Syndrome Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Type in 2022
1.3.3 Alosetron
1.3.4 Lubiprostone
1.3.5 Linaclotide
1.3.6 Others
1.4 Global Drugs for Irritable Bowel Syndrome Market by Application
1.4.1 Overview: Global Drugs for Irritable Bowel Syndrome Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital
1.4.3 Clinic
1.4.4 Others
1.5 Global Drugs for Irritable Bowel Syndrome Market Size & Forecast
1.6 Global Drugs for Irritable Bowel Syndrome Market Size and Forecast by Region
1.6.1 Global Drugs for Irritable Bowel Syndrome Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Drugs for Irritable Bowel Syndrome Market Size by Region, (2018-2029)
1.6.3 North America Drugs for Irritable Bowel Syndrome Market Size and Prospect (2018-2029)
1.6.4 Europe Drugs for Irritable Bowel Syndrome Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Drugs for Irritable Bowel Syndrome Market Size and Prospect (2018-2029)
1.6.6 South America Drugs for Irritable Bowel Syndrome Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Drugs for Irritable Bowel Syndrome Market Size and Prospect (2018-2029)
2 COMPANY PROFILES
2.1 Takeda Pharmaceutical Company Limited
2.1.1 Takeda Pharmaceutical Company Limited Details
2.1.2 Takeda Pharmaceutical Company Limited Major Business
2.1.3 Takeda Pharmaceutical Company Limited Drugs for Irritable Bowel Syndrome Product and Solutions
2.1.4 Takeda Pharmaceutical Company Limited Drugs for Irritable Bowel Syndrome Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Takeda Pharmaceutical Company Limited Recent Developments and Future Plans
2.2 Pfizer, Inc.
2.2.1 Pfizer, Inc. Details
2.2.2 Pfizer, Inc. Major Business
2.2.3 Pfizer, Inc. Drugs for Irritable Bowel Syndrome Product and Solutions
2.2.4 Pfizer, Inc. Drugs for Irritable Bowel Syndrome Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Pfizer, Inc. Recent Developments and Future Plans
2.3 Abbott Laboratories
2.3.1 Abbott Laboratories Details
2.3.2 Abbott Laboratories Major Business
2.3.3 Abbott Laboratories Drugs for Irritable Bowel Syndrome Product and Solutions
2.3.4 Abbott Laboratories Drugs for Irritable Bowel Syndrome Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Abbott Laboratories Recent Developments and Future Plans
2.4 Novartis AG
2.4.1 Novartis AG Details
2.4.2 Novartis AG Major Business
2.4.3 Novartis AG Drugs for Irritable Bowel Syndrome Product and Solutions
2.4.4 Novartis AG Drugs for Irritable Bowel Syndrome Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Novartis AG Recent Developments and Future Plans
2.5 AstraZeneca PLC
2.5.1 AstraZeneca PLC Details
2.5.2 AstraZeneca PLC Major Business
2.5.3 AstraZeneca PLC Drugs for Irritable Bowel Syndrome Product and Solutions
2.5.4 AstraZeneca PLC Drugs for Irritable Bowel Syndrome Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 AstraZeneca PLC Recent Developments and Future Plans
2.6 Ironwood Pharmaceuticals Inc. and Allergan Plc
2.6.1 Ironwood Pharmaceuticals Inc. and Allergan Plc Details
2.6.2 Ironwood Pharmaceuticals Inc. and Allergan Plc Major Business
2.6.3 Ironwood Pharmaceuticals Inc. and Allergan Plc Drugs for Irritable Bowel Syndrome Product and Solutions
2.6.4 Ironwood Pharmaceuticals Inc. and Allergan Plc Drugs for Irritable Bowel Syndrome Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Ironwood Pharmaceuticals Inc. and Allergan Plc Recent Developments and Future Plans
2.7 Bausch Health Companies Inc.
2.7.1 Bausch Health Companies Inc. Details
2.7.2 Bausch Health Companies Inc. Major Business
2.7.3 Bausch Health Companies Inc. Drugs for Irritable Bowel Syndrome Product and Solutions
2.7.4 Bausch Health Companies Inc. Drugs for Irritable Bowel Syndrome Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Bausch Health Companies Inc. Recent Developments and Future Plans
2.8 GlaxoSmithKline, Plc.
2.8.1 GlaxoSmithKline, Plc. Details
2.8.2 GlaxoSmithKline, Plc. Major Business
2.8.3 GlaxoSmithKline, Plc. Drugs for Irritable Bowel Syndrome Product and Solutions
2.8.4 GlaxoSmithKline, Plc. Drugs for Irritable Bowel Syndrome Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 GlaxoSmithKline, Plc. Recent Developments and Future Plans
2.9 Lexicon Pharmaceuticals, Inc.
2.9.1 Lexicon Pharmaceuticals, Inc. Details
2.9.2 Lexicon Pharmaceuticals, Inc. Major Business
2.9.3 Lexicon Pharmaceuticals, Inc. Drugs for Irritable Bowel Syndrome Product and Solutions
2.9.4 Lexicon Pharmaceuticals, Inc. Drugs for Irritable Bowel Syndrome Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Lexicon Pharmaceuticals, Inc. Recent Developments and Future Plans
2.10 Sucampo Pharmaceuticals, Inc.
2.10.1 Sucampo Pharmaceuticals, Inc. Details
2.10.2 Sucampo Pharmaceuticals, Inc. Major Business
2.10.3 Sucampo Pharmaceuticals, Inc. Drugs for Irritable Bowel Syndrome Product and Solutions
2.10.4 Sucampo Pharmaceuticals, Inc. Drugs for Irritable Bowel Syndrome Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Sucampo Pharmaceuticals, Inc. Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Drugs for Irritable Bowel Syndrome Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Drugs for Irritable Bowel Syndrome by Company Revenue
3.2.2 Top 3 Drugs for Irritable Bowel Syndrome Players Market Share in 2022
3.2.3 Top 6 Drugs for Irritable Bowel Syndrome Players Market Share in 2022
3.3 Drugs for Irritable Bowel Syndrome Market: Overall Company Footprint Analysis
3.3.1 Drugs for Irritable Bowel Syndrome Market: Region Footprint
3.3.2 Drugs for Irritable Bowel Syndrome Market: Company Product Type Footprint
3.3.3 Drugs for Irritable Bowel Syndrome Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Drugs for Irritable Bowel Syndrome Consumption Value and Market Share by Type (2018-2023)
4.2 Global Drugs for Irritable Bowel Syndrome Market Forecast by Type (2024-2029)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Application (2018-2023)
5.2 Global Drugs for Irritable Bowel Syndrome Market Forecast by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Drugs for Irritable Bowel Syndrome Consumption Value by Type (2018-2029)
6.2 North America Drugs for Irritable Bowel Syndrome Consumption Value by Application (2018-2029)
6.3 North America Drugs for Irritable Bowel Syndrome Market Size by Country
6.3.1 North America Drugs for Irritable Bowel Syndrome Consumption Value by Country (2018-2029)
6.3.2 United States Drugs for Irritable Bowel Syndrome Market Size and Forecast (2018-2029)
6.3.3 Canada Drugs for Irritable Bowel Syndrome Market Size and Forecast (2018-2029)
6.3.4 Mexico Drugs for Irritable Bowel Syndrome Market Size and Forecast (2018-2029)
7 EUROPE
7.1 Europe Drugs for Irritable Bowel Syndrome Consumption Value by Type (2018-2029)
7.2 Europe Drugs for Irritable Bowel Syndrome Consumption Value by Application (2018-2029)
7.3 Europe Drugs for Irritable Bowel Syndrome Market Size by Country
7.3.1 Europe Drugs for Irritable Bowel Syndrome Consumption Value by Country (2018-2029)
7.3.2 Germany Drugs for Irritable Bowel Syndrome Market Size and Forecast (2018-2029)
7.3.3 France Drugs for Irritable Bowel Syndrome Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Drugs for Irritable Bowel Syndrome Market Size and Forecast (2018-2029)
7.3.5 Russia Drugs for Irritable Bowel Syndrome Market Size and Forecast (2018-2029)
7.3.6 Italy Drugs for Irritable Bowel Syndrome Market Size and Forecast (2018-2029)
8 ASIA-PACIFIC
8.1 Asia-Pacific Drugs for Irritable Bowel Syndrome Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Drugs for Irritable Bowel Syndrome Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Drugs for Irritable Bowel Syndrome Market Size by Region
8.3.1 Asia-Pacific Drugs for Irritable Bowel Syndrome Consumption Value by Region (2018-2029)
8.3.2 China Drugs for Irritable Bowel Syndrome Market Size and Forecast (2018-2029)
8.3.3 Japan Drugs for Irritable Bowel Syndrome Market Size and Forecast (2018-2029)
8.3.4 South Korea Drugs for Irritable Bowel Syndrome Market Size and Forecast (2018-2029)
8.3.5 India Drugs for Irritable Bowel Syndrome Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Drugs for Irritable Bowel Syndrome Market Size and Forecast (2018-2029)
8.3.7 Australia Drugs for Irritable Bowel Syndrome Market Size and Forecast (2018-2029)
9 SOUTH AMERICA
9.1 South America Drugs for Irritable Bowel Syndrome Consumption Value by Type (2018-2029)
9.2 South America Drugs for Irritable Bowel Syndrome Consumption Value by Application (2018-2029)
9.3 South America Drugs for Irritable Bowel Syndrome Market Size by Country
9.3.1 South America Drugs for Irritable Bowel Syndrome Consumption Value by Country (2018-2029)
9.3.2 Brazil Drugs for Irritable Bowel Syndrome Market Size and Forecast (2018-2029)
9.3.3 Argentina Drugs for Irritable Bowel Syndrome Market Size and Forecast (2018-2029)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Drugs for Irritable Bowel Syndrome Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Drugs for Irritable Bowel Syndrome Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Drugs for Irritable Bowel Syndrome Market Size by Country
10.3.1 Middle East & Africa Drugs for Irritable Bowel Syndrome Consumption Value by Country (2018-2029)
10.3.2 Turkey Drugs for Irritable Bowel Syndrome Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Drugs for Irritable Bowel Syndrome Market Size and Forecast (2018-2029)
10.3.4 UAE Drugs for Irritable Bowel Syndrome Market Size and Forecast (2018-2029)
11 MARKET DYNAMICS
11.1 Drugs for Irritable Bowel Syndrome Market Drivers
11.2 Drugs for Irritable Bowel Syndrome Market Restraints
11.3 Drugs for Irritable Bowel Syndrome Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 INDUSTRY CHAIN ANALYSIS
12.1 Drugs for Irritable Bowel Syndrome Industry Chain
12.2 Drugs for Irritable Bowel Syndrome Upstream Analysis
12.3 Drugs for Irritable Bowel Syndrome Midstream Analysis
12.4 Drugs for Irritable Bowel Syndrome Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope of Drugs for Irritable Bowel Syndrome
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Drugs for Irritable Bowel Syndrome by Type
1.3.1 Overview: Global Drugs for Irritable Bowel Syndrome Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Type in 2022
1.3.3 Alosetron
1.3.4 Lubiprostone
1.3.5 Linaclotide
1.3.6 Others
1.4 Global Drugs for Irritable Bowel Syndrome Market by Application
1.4.1 Overview: Global Drugs for Irritable Bowel Syndrome Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital
1.4.3 Clinic
1.4.4 Others
1.5 Global Drugs for Irritable Bowel Syndrome Market Size & Forecast
1.6 Global Drugs for Irritable Bowel Syndrome Market Size and Forecast by Region
1.6.1 Global Drugs for Irritable Bowel Syndrome Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Drugs for Irritable Bowel Syndrome Market Size by Region, (2018-2029)
1.6.3 North America Drugs for Irritable Bowel Syndrome Market Size and Prospect (2018-2029)
1.6.4 Europe Drugs for Irritable Bowel Syndrome Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Drugs for Irritable Bowel Syndrome Market Size and Prospect (2018-2029)
1.6.6 South America Drugs for Irritable Bowel Syndrome Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Drugs for Irritable Bowel Syndrome Market Size and Prospect (2018-2029)
2 COMPANY PROFILES
2.1 Takeda Pharmaceutical Company Limited
2.1.1 Takeda Pharmaceutical Company Limited Details
2.1.2 Takeda Pharmaceutical Company Limited Major Business
2.1.3 Takeda Pharmaceutical Company Limited Drugs for Irritable Bowel Syndrome Product and Solutions
2.1.4 Takeda Pharmaceutical Company Limited Drugs for Irritable Bowel Syndrome Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Takeda Pharmaceutical Company Limited Recent Developments and Future Plans
2.2 Pfizer, Inc.
2.2.1 Pfizer, Inc. Details
2.2.2 Pfizer, Inc. Major Business
2.2.3 Pfizer, Inc. Drugs for Irritable Bowel Syndrome Product and Solutions
2.2.4 Pfizer, Inc. Drugs for Irritable Bowel Syndrome Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Pfizer, Inc. Recent Developments and Future Plans
2.3 Abbott Laboratories
2.3.1 Abbott Laboratories Details
2.3.2 Abbott Laboratories Major Business
2.3.3 Abbott Laboratories Drugs for Irritable Bowel Syndrome Product and Solutions
2.3.4 Abbott Laboratories Drugs for Irritable Bowel Syndrome Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Abbott Laboratories Recent Developments and Future Plans
2.4 Novartis AG
2.4.1 Novartis AG Details
2.4.2 Novartis AG Major Business
2.4.3 Novartis AG Drugs for Irritable Bowel Syndrome Product and Solutions
2.4.4 Novartis AG Drugs for Irritable Bowel Syndrome Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Novartis AG Recent Developments and Future Plans
2.5 AstraZeneca PLC
2.5.1 AstraZeneca PLC Details
2.5.2 AstraZeneca PLC Major Business
2.5.3 AstraZeneca PLC Drugs for Irritable Bowel Syndrome Product and Solutions
2.5.4 AstraZeneca PLC Drugs for Irritable Bowel Syndrome Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 AstraZeneca PLC Recent Developments and Future Plans
2.6 Ironwood Pharmaceuticals Inc. and Allergan Plc
2.6.1 Ironwood Pharmaceuticals Inc. and Allergan Plc Details
2.6.2 Ironwood Pharmaceuticals Inc. and Allergan Plc Major Business
2.6.3 Ironwood Pharmaceuticals Inc. and Allergan Plc Drugs for Irritable Bowel Syndrome Product and Solutions
2.6.4 Ironwood Pharmaceuticals Inc. and Allergan Plc Drugs for Irritable Bowel Syndrome Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Ironwood Pharmaceuticals Inc. and Allergan Plc Recent Developments and Future Plans
2.7 Bausch Health Companies Inc.
2.7.1 Bausch Health Companies Inc. Details
2.7.2 Bausch Health Companies Inc. Major Business
2.7.3 Bausch Health Companies Inc. Drugs for Irritable Bowel Syndrome Product and Solutions
2.7.4 Bausch Health Companies Inc. Drugs for Irritable Bowel Syndrome Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Bausch Health Companies Inc. Recent Developments and Future Plans
2.8 GlaxoSmithKline, Plc.
2.8.1 GlaxoSmithKline, Plc. Details
2.8.2 GlaxoSmithKline, Plc. Major Business
2.8.3 GlaxoSmithKline, Plc. Drugs for Irritable Bowel Syndrome Product and Solutions
2.8.4 GlaxoSmithKline, Plc. Drugs for Irritable Bowel Syndrome Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 GlaxoSmithKline, Plc. Recent Developments and Future Plans
2.9 Lexicon Pharmaceuticals, Inc.
2.9.1 Lexicon Pharmaceuticals, Inc. Details
2.9.2 Lexicon Pharmaceuticals, Inc. Major Business
2.9.3 Lexicon Pharmaceuticals, Inc. Drugs for Irritable Bowel Syndrome Product and Solutions
2.9.4 Lexicon Pharmaceuticals, Inc. Drugs for Irritable Bowel Syndrome Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Lexicon Pharmaceuticals, Inc. Recent Developments and Future Plans
2.10 Sucampo Pharmaceuticals, Inc.
2.10.1 Sucampo Pharmaceuticals, Inc. Details
2.10.2 Sucampo Pharmaceuticals, Inc. Major Business
2.10.3 Sucampo Pharmaceuticals, Inc. Drugs for Irritable Bowel Syndrome Product and Solutions
2.10.4 Sucampo Pharmaceuticals, Inc. Drugs for Irritable Bowel Syndrome Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Sucampo Pharmaceuticals, Inc. Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Drugs for Irritable Bowel Syndrome Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Drugs for Irritable Bowel Syndrome by Company Revenue
3.2.2 Top 3 Drugs for Irritable Bowel Syndrome Players Market Share in 2022
3.2.3 Top 6 Drugs for Irritable Bowel Syndrome Players Market Share in 2022
3.3 Drugs for Irritable Bowel Syndrome Market: Overall Company Footprint Analysis
3.3.1 Drugs for Irritable Bowel Syndrome Market: Region Footprint
3.3.2 Drugs for Irritable Bowel Syndrome Market: Company Product Type Footprint
3.3.3 Drugs for Irritable Bowel Syndrome Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Drugs for Irritable Bowel Syndrome Consumption Value and Market Share by Type (2018-2023)
4.2 Global Drugs for Irritable Bowel Syndrome Market Forecast by Type (2024-2029)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Application (2018-2023)
5.2 Global Drugs for Irritable Bowel Syndrome Market Forecast by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Drugs for Irritable Bowel Syndrome Consumption Value by Type (2018-2029)
6.2 North America Drugs for Irritable Bowel Syndrome Consumption Value by Application (2018-2029)
6.3 North America Drugs for Irritable Bowel Syndrome Market Size by Country
6.3.1 North America Drugs for Irritable Bowel Syndrome Consumption Value by Country (2018-2029)
6.3.2 United States Drugs for Irritable Bowel Syndrome Market Size and Forecast (2018-2029)
6.3.3 Canada Drugs for Irritable Bowel Syndrome Market Size and Forecast (2018-2029)
6.3.4 Mexico Drugs for Irritable Bowel Syndrome Market Size and Forecast (2018-2029)
7 EUROPE
7.1 Europe Drugs for Irritable Bowel Syndrome Consumption Value by Type (2018-2029)
7.2 Europe Drugs for Irritable Bowel Syndrome Consumption Value by Application (2018-2029)
7.3 Europe Drugs for Irritable Bowel Syndrome Market Size by Country
7.3.1 Europe Drugs for Irritable Bowel Syndrome Consumption Value by Country (2018-2029)
7.3.2 Germany Drugs for Irritable Bowel Syndrome Market Size and Forecast (2018-2029)
7.3.3 France Drugs for Irritable Bowel Syndrome Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Drugs for Irritable Bowel Syndrome Market Size and Forecast (2018-2029)
7.3.5 Russia Drugs for Irritable Bowel Syndrome Market Size and Forecast (2018-2029)
7.3.6 Italy Drugs for Irritable Bowel Syndrome Market Size and Forecast (2018-2029)
8 ASIA-PACIFIC
8.1 Asia-Pacific Drugs for Irritable Bowel Syndrome Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Drugs for Irritable Bowel Syndrome Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Drugs for Irritable Bowel Syndrome Market Size by Region
8.3.1 Asia-Pacific Drugs for Irritable Bowel Syndrome Consumption Value by Region (2018-2029)
8.3.2 China Drugs for Irritable Bowel Syndrome Market Size and Forecast (2018-2029)
8.3.3 Japan Drugs for Irritable Bowel Syndrome Market Size and Forecast (2018-2029)
8.3.4 South Korea Drugs for Irritable Bowel Syndrome Market Size and Forecast (2018-2029)
8.3.5 India Drugs for Irritable Bowel Syndrome Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Drugs for Irritable Bowel Syndrome Market Size and Forecast (2018-2029)
8.3.7 Australia Drugs for Irritable Bowel Syndrome Market Size and Forecast (2018-2029)
9 SOUTH AMERICA
9.1 South America Drugs for Irritable Bowel Syndrome Consumption Value by Type (2018-2029)
9.2 South America Drugs for Irritable Bowel Syndrome Consumption Value by Application (2018-2029)
9.3 South America Drugs for Irritable Bowel Syndrome Market Size by Country
9.3.1 South America Drugs for Irritable Bowel Syndrome Consumption Value by Country (2018-2029)
9.3.2 Brazil Drugs for Irritable Bowel Syndrome Market Size and Forecast (2018-2029)
9.3.3 Argentina Drugs for Irritable Bowel Syndrome Market Size and Forecast (2018-2029)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Drugs for Irritable Bowel Syndrome Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Drugs for Irritable Bowel Syndrome Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Drugs for Irritable Bowel Syndrome Market Size by Country
10.3.1 Middle East & Africa Drugs for Irritable Bowel Syndrome Consumption Value by Country (2018-2029)
10.3.2 Turkey Drugs for Irritable Bowel Syndrome Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Drugs for Irritable Bowel Syndrome Market Size and Forecast (2018-2029)
10.3.4 UAE Drugs for Irritable Bowel Syndrome Market Size and Forecast (2018-2029)
11 MARKET DYNAMICS
11.1 Drugs for Irritable Bowel Syndrome Market Drivers
11.2 Drugs for Irritable Bowel Syndrome Market Restraints
11.3 Drugs for Irritable Bowel Syndrome Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 INDUSTRY CHAIN ANALYSIS
12.1 Drugs for Irritable Bowel Syndrome Industry Chain
12.2 Drugs for Irritable Bowel Syndrome Upstream Analysis
12.3 Drugs for Irritable Bowel Syndrome Midstream Analysis
12.4 Drugs for Irritable Bowel Syndrome Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Drugs for Irritable Bowel Syndrome Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Drugs for Irritable Bowel Syndrome Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Drugs for Irritable Bowel Syndrome Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Drugs for Irritable Bowel Syndrome Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Takeda Pharmaceutical Company Limited Company Information, Head Office, and Major Competitors
Table 6. Takeda Pharmaceutical Company Limited Major Business
Table 7. Takeda Pharmaceutical Company Limited Drugs for Irritable Bowel Syndrome Product and Solutions
Table 8. Takeda Pharmaceutical Company Limited Drugs for Irritable Bowel Syndrome Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Takeda Pharmaceutical Company Limited Recent Developments and Future Plans
Table 10. Pfizer, Inc. Company Information, Head Office, and Major Competitors
Table 11. Pfizer, Inc. Major Business
Table 12. Pfizer, Inc. Drugs for Irritable Bowel Syndrome Product and Solutions
Table 13. Pfizer, Inc. Drugs for Irritable Bowel Syndrome Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Pfizer, Inc. Recent Developments and Future Plans
Table 15. Abbott Laboratories Company Information, Head Office, and Major Competitors
Table 16. Abbott Laboratories Major Business
Table 17. Abbott Laboratories Drugs for Irritable Bowel Syndrome Product and Solutions
Table 18. Abbott Laboratories Drugs for Irritable Bowel Syndrome Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Abbott Laboratories Recent Developments and Future Plans
Table 20. Novartis AG Company Information, Head Office, and Major Competitors
Table 21. Novartis AG Major Business
Table 22. Novartis AG Drugs for Irritable Bowel Syndrome Product and Solutions
Table 23. Novartis AG Drugs for Irritable Bowel Syndrome Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Novartis AG Recent Developments and Future Plans
Table 25. AstraZeneca PLC Company Information, Head Office, and Major Competitors
Table 26. AstraZeneca PLC Major Business
Table 27. AstraZeneca PLC Drugs for Irritable Bowel Syndrome Product and Solutions
Table 28. AstraZeneca PLC Drugs for Irritable Bowel Syndrome Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. AstraZeneca PLC Recent Developments and Future Plans
Table 30. Ironwood Pharmaceuticals Inc. and Allergan Plc Company Information, Head Office, and Major Competitors
Table 31. Ironwood Pharmaceuticals Inc. and Allergan Plc Major Business
Table 32. Ironwood Pharmaceuticals Inc. and Allergan Plc Drugs for Irritable Bowel Syndrome Product and Solutions
Table 33. Ironwood Pharmaceuticals Inc. and Allergan Plc Drugs for Irritable Bowel Syndrome Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Ironwood Pharmaceuticals Inc. and Allergan Plc Recent Developments and Future Plans
Table 35. Bausch Health Companies Inc. Company Information, Head Office, and Major Competitors
Table 36. Bausch Health Companies Inc. Major Business
Table 37. Bausch Health Companies Inc. Drugs for Irritable Bowel Syndrome Product and Solutions
Table 38. Bausch Health Companies Inc. Drugs for Irritable Bowel Syndrome Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Bausch Health Companies Inc. Recent Developments and Future Plans
Table 40. GlaxoSmithKline, Plc. Company Information, Head Office, and Major Competitors
Table 41. GlaxoSmithKline, Plc. Major Business
Table 42. GlaxoSmithKline, Plc. Drugs for Irritable Bowel Syndrome Product and Solutions
Table 43. GlaxoSmithKline, Plc. Drugs for Irritable Bowel Syndrome Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. GlaxoSmithKline, Plc. Recent Developments and Future Plans
Table 45. Lexicon Pharmaceuticals, Inc. Company Information, Head Office, and Major Competitors
Table 46. Lexicon Pharmaceuticals, Inc. Major Business
Table 47. Lexicon Pharmaceuticals, Inc. Drugs for Irritable Bowel Syndrome Product and Solutions
Table 48. Lexicon Pharmaceuticals, Inc. Drugs for Irritable Bowel Syndrome Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Lexicon Pharmaceuticals, Inc. Recent Developments and Future Plans
Table 50. Sucampo Pharmaceuticals, Inc. Company Information, Head Office, and Major Competitors
Table 51. Sucampo Pharmaceuticals, Inc. Major Business
Table 52. Sucampo Pharmaceuticals, Inc. Drugs for Irritable Bowel Syndrome Product and Solutions
Table 53. Sucampo Pharmaceuticals, Inc. Drugs for Irritable Bowel Syndrome Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Sucampo Pharmaceuticals, Inc. Recent Developments and Future Plans
Table 55. Global Drugs for Irritable Bowel Syndrome Revenue (USD Million) by Players (2018-2023)
Table 56. Global Drugs for Irritable Bowel Syndrome Revenue Share by Players (2018-2023)
Table 57. Breakdown of Drugs for Irritable Bowel Syndrome by Company Type (Tier 1, Tier 2, and Tier 3)
Table 58. Market Position of Players in Drugs for Irritable Bowel Syndrome, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 59. Head Office of Key Drugs for Irritable Bowel Syndrome Players
Table 60. Drugs for Irritable Bowel Syndrome Market: Company Product Type Footprint
Table 61. Drugs for Irritable Bowel Syndrome Market: Company Product Application Footprint
Table 62. Drugs for Irritable Bowel Syndrome New Market Entrants and Barriers to Market Entry
Table 63. Drugs for Irritable Bowel Syndrome Mergers, Acquisition, Agreements, and Collaborations
Table 64. Global Drugs for Irritable Bowel Syndrome Consumption Value (USD Million) by Type (2018-2023)
Table 65. Global Drugs for Irritable Bowel Syndrome Consumption Value Share by Type (2018-2023)
Table 66. Global Drugs for Irritable Bowel Syndrome Consumption Value Forecast by Type (2024-2029)
Table 67. Global Drugs for Irritable Bowel Syndrome Consumption Value by Application (2018-2023)
Table 68. Global Drugs for Irritable Bowel Syndrome Consumption Value Forecast by Application (2024-2029)
Table 69. North America Drugs for Irritable Bowel Syndrome Consumption Value by Type (2018-2023) & (USD Million)
Table 70. North America Drugs for Irritable Bowel Syndrome Consumption Value by Type (2024-2029) & (USD Million)
Table 71. North America Drugs for Irritable Bowel Syndrome Consumption Value by Application (2018-2023) & (USD Million)
Table 72. North America Drugs for Irritable Bowel Syndrome Consumption Value by Application (2024-2029) & (USD Million)
Table 73. North America Drugs for Irritable Bowel Syndrome Consumption Value by Country (2018-2023) & (USD Million)
Table 74. North America Drugs for Irritable Bowel Syndrome Consumption Value by Country (2024-2029) & (USD Million)
Table 75. Europe Drugs for Irritable Bowel Syndrome Consumption Value by Type (2018-2023) & (USD Million)
Table 76. Europe Drugs for Irritable Bowel Syndrome Consumption Value by Type (2024-2029) & (USD Million)
Table 77. Europe Drugs for Irritable Bowel Syndrome Consumption Value by Application (2018-2023) & (USD Million)
Table 78. Europe Drugs for Irritable Bowel Syndrome Consumption Value by Application (2024-2029) & (USD Million)
Table 79. Europe Drugs for Irritable Bowel Syndrome Consumption Value by Country (2018-2023) & (USD Million)
Table 80. Europe Drugs for Irritable Bowel Syndrome Consumption Value by Country (2024-2029) & (USD Million)
Table 81. Asia-Pacific Drugs for Irritable Bowel Syndrome Consumption Value by Type (2018-2023) & (USD Million)
Table 82. Asia-Pacific Drugs for Irritable Bowel Syndrome Consumption Value by Type (2024-2029) & (USD Million)
Table 83. Asia-Pacific Drugs for Irritable Bowel Syndrome Consumption Value by Application (2018-2023) & (USD Million)
Table 84. Asia-Pacific Drugs for Irritable Bowel Syndrome Consumption Value by Application (2024-2029) & (USD Million)
Table 85. Asia-Pacific Drugs for Irritable Bowel Syndrome Consumption Value by Region (2018-2023) & (USD Million)
Table 86. Asia-Pacific Drugs for Irritable Bowel Syndrome Consumption Value by Region (2024-2029) & (USD Million)
Table 87. South America Drugs for Irritable Bowel Syndrome Consumption Value by Type (2018-2023) & (USD Million)
Table 88. South America Drugs for Irritable Bowel Syndrome Consumption Value by Type (2024-2029) & (USD Million)
Table 89. South America Drugs for Irritable Bowel Syndrome Consumption Value by Application (2018-2023) & (USD Million)
Table 90. South America Drugs for Irritable Bowel Syndrome Consumption Value by Application (2024-2029) & (USD Million)
Table 91. South America Drugs for Irritable Bowel Syndrome Consumption Value by Country (2018-2023) & (USD Million)
Table 92. South America Drugs for Irritable Bowel Syndrome Consumption Value by Country (2024-2029) & (USD Million)
Table 93. Middle East & Africa Drugs for Irritable Bowel Syndrome Consumption Value by Type (2018-2023) & (USD Million)
Table 94. Middle East & Africa Drugs for Irritable Bowel Syndrome Consumption Value by Type (2024-2029) & (USD Million)
Table 95. Middle East & Africa Drugs for Irritable Bowel Syndrome Consumption Value by Application (2018-2023) & (USD Million)
Table 96. Middle East & Africa Drugs for Irritable Bowel Syndrome Consumption Value by Application (2024-2029) & (USD Million)
Table 97. Middle East & Africa Drugs for Irritable Bowel Syndrome Consumption Value by Country (2018-2023) & (USD Million)
Table 98. Middle East & Africa Drugs for Irritable Bowel Syndrome Consumption Value by Country (2024-2029) & (USD Million)
Table 99. Drugs for Irritable Bowel Syndrome Raw Material
Table 100. Key Suppliers of Drugs for Irritable Bowel Syndrome Raw Materials
Table 1. Global Drugs for Irritable Bowel Syndrome Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Drugs for Irritable Bowel Syndrome Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Drugs for Irritable Bowel Syndrome Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Drugs for Irritable Bowel Syndrome Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Takeda Pharmaceutical Company Limited Company Information, Head Office, and Major Competitors
Table 6. Takeda Pharmaceutical Company Limited Major Business
Table 7. Takeda Pharmaceutical Company Limited Drugs for Irritable Bowel Syndrome Product and Solutions
Table 8. Takeda Pharmaceutical Company Limited Drugs for Irritable Bowel Syndrome Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Takeda Pharmaceutical Company Limited Recent Developments and Future Plans
Table 10. Pfizer, Inc. Company Information, Head Office, and Major Competitors
Table 11. Pfizer, Inc. Major Business
Table 12. Pfizer, Inc. Drugs for Irritable Bowel Syndrome Product and Solutions
Table 13. Pfizer, Inc. Drugs for Irritable Bowel Syndrome Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Pfizer, Inc. Recent Developments and Future Plans
Table 15. Abbott Laboratories Company Information, Head Office, and Major Competitors
Table 16. Abbott Laboratories Major Business
Table 17. Abbott Laboratories Drugs for Irritable Bowel Syndrome Product and Solutions
Table 18. Abbott Laboratories Drugs for Irritable Bowel Syndrome Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Abbott Laboratories Recent Developments and Future Plans
Table 20. Novartis AG Company Information, Head Office, and Major Competitors
Table 21. Novartis AG Major Business
Table 22. Novartis AG Drugs for Irritable Bowel Syndrome Product and Solutions
Table 23. Novartis AG Drugs for Irritable Bowel Syndrome Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Novartis AG Recent Developments and Future Plans
Table 25. AstraZeneca PLC Company Information, Head Office, and Major Competitors
Table 26. AstraZeneca PLC Major Business
Table 27. AstraZeneca PLC Drugs for Irritable Bowel Syndrome Product and Solutions
Table 28. AstraZeneca PLC Drugs for Irritable Bowel Syndrome Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. AstraZeneca PLC Recent Developments and Future Plans
Table 30. Ironwood Pharmaceuticals Inc. and Allergan Plc Company Information, Head Office, and Major Competitors
Table 31. Ironwood Pharmaceuticals Inc. and Allergan Plc Major Business
Table 32. Ironwood Pharmaceuticals Inc. and Allergan Plc Drugs for Irritable Bowel Syndrome Product and Solutions
Table 33. Ironwood Pharmaceuticals Inc. and Allergan Plc Drugs for Irritable Bowel Syndrome Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Ironwood Pharmaceuticals Inc. and Allergan Plc Recent Developments and Future Plans
Table 35. Bausch Health Companies Inc. Company Information, Head Office, and Major Competitors
Table 36. Bausch Health Companies Inc. Major Business
Table 37. Bausch Health Companies Inc. Drugs for Irritable Bowel Syndrome Product and Solutions
Table 38. Bausch Health Companies Inc. Drugs for Irritable Bowel Syndrome Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Bausch Health Companies Inc. Recent Developments and Future Plans
Table 40. GlaxoSmithKline, Plc. Company Information, Head Office, and Major Competitors
Table 41. GlaxoSmithKline, Plc. Major Business
Table 42. GlaxoSmithKline, Plc. Drugs for Irritable Bowel Syndrome Product and Solutions
Table 43. GlaxoSmithKline, Plc. Drugs for Irritable Bowel Syndrome Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. GlaxoSmithKline, Plc. Recent Developments and Future Plans
Table 45. Lexicon Pharmaceuticals, Inc. Company Information, Head Office, and Major Competitors
Table 46. Lexicon Pharmaceuticals, Inc. Major Business
Table 47. Lexicon Pharmaceuticals, Inc. Drugs for Irritable Bowel Syndrome Product and Solutions
Table 48. Lexicon Pharmaceuticals, Inc. Drugs for Irritable Bowel Syndrome Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Lexicon Pharmaceuticals, Inc. Recent Developments and Future Plans
Table 50. Sucampo Pharmaceuticals, Inc. Company Information, Head Office, and Major Competitors
Table 51. Sucampo Pharmaceuticals, Inc. Major Business
Table 52. Sucampo Pharmaceuticals, Inc. Drugs for Irritable Bowel Syndrome Product and Solutions
Table 53. Sucampo Pharmaceuticals, Inc. Drugs for Irritable Bowel Syndrome Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Sucampo Pharmaceuticals, Inc. Recent Developments and Future Plans
Table 55. Global Drugs for Irritable Bowel Syndrome Revenue (USD Million) by Players (2018-2023)
Table 56. Global Drugs for Irritable Bowel Syndrome Revenue Share by Players (2018-2023)
Table 57. Breakdown of Drugs for Irritable Bowel Syndrome by Company Type (Tier 1, Tier 2, and Tier 3)
Table 58. Market Position of Players in Drugs for Irritable Bowel Syndrome, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 59. Head Office of Key Drugs for Irritable Bowel Syndrome Players
Table 60. Drugs for Irritable Bowel Syndrome Market: Company Product Type Footprint
Table 61. Drugs for Irritable Bowel Syndrome Market: Company Product Application Footprint
Table 62. Drugs for Irritable Bowel Syndrome New Market Entrants and Barriers to Market Entry
Table 63. Drugs for Irritable Bowel Syndrome Mergers, Acquisition, Agreements, and Collaborations
Table 64. Global Drugs for Irritable Bowel Syndrome Consumption Value (USD Million) by Type (2018-2023)
Table 65. Global Drugs for Irritable Bowel Syndrome Consumption Value Share by Type (2018-2023)
Table 66. Global Drugs for Irritable Bowel Syndrome Consumption Value Forecast by Type (2024-2029)
Table 67. Global Drugs for Irritable Bowel Syndrome Consumption Value by Application (2018-2023)
Table 68. Global Drugs for Irritable Bowel Syndrome Consumption Value Forecast by Application (2024-2029)
Table 69. North America Drugs for Irritable Bowel Syndrome Consumption Value by Type (2018-2023) & (USD Million)
Table 70. North America Drugs for Irritable Bowel Syndrome Consumption Value by Type (2024-2029) & (USD Million)
Table 71. North America Drugs for Irritable Bowel Syndrome Consumption Value by Application (2018-2023) & (USD Million)
Table 72. North America Drugs for Irritable Bowel Syndrome Consumption Value by Application (2024-2029) & (USD Million)
Table 73. North America Drugs for Irritable Bowel Syndrome Consumption Value by Country (2018-2023) & (USD Million)
Table 74. North America Drugs for Irritable Bowel Syndrome Consumption Value by Country (2024-2029) & (USD Million)
Table 75. Europe Drugs for Irritable Bowel Syndrome Consumption Value by Type (2018-2023) & (USD Million)
Table 76. Europe Drugs for Irritable Bowel Syndrome Consumption Value by Type (2024-2029) & (USD Million)
Table 77. Europe Drugs for Irritable Bowel Syndrome Consumption Value by Application (2018-2023) & (USD Million)
Table 78. Europe Drugs for Irritable Bowel Syndrome Consumption Value by Application (2024-2029) & (USD Million)
Table 79. Europe Drugs for Irritable Bowel Syndrome Consumption Value by Country (2018-2023) & (USD Million)
Table 80. Europe Drugs for Irritable Bowel Syndrome Consumption Value by Country (2024-2029) & (USD Million)
Table 81. Asia-Pacific Drugs for Irritable Bowel Syndrome Consumption Value by Type (2018-2023) & (USD Million)
Table 82. Asia-Pacific Drugs for Irritable Bowel Syndrome Consumption Value by Type (2024-2029) & (USD Million)
Table 83. Asia-Pacific Drugs for Irritable Bowel Syndrome Consumption Value by Application (2018-2023) & (USD Million)
Table 84. Asia-Pacific Drugs for Irritable Bowel Syndrome Consumption Value by Application (2024-2029) & (USD Million)
Table 85. Asia-Pacific Drugs for Irritable Bowel Syndrome Consumption Value by Region (2018-2023) & (USD Million)
Table 86. Asia-Pacific Drugs for Irritable Bowel Syndrome Consumption Value by Region (2024-2029) & (USD Million)
Table 87. South America Drugs for Irritable Bowel Syndrome Consumption Value by Type (2018-2023) & (USD Million)
Table 88. South America Drugs for Irritable Bowel Syndrome Consumption Value by Type (2024-2029) & (USD Million)
Table 89. South America Drugs for Irritable Bowel Syndrome Consumption Value by Application (2018-2023) & (USD Million)
Table 90. South America Drugs for Irritable Bowel Syndrome Consumption Value by Application (2024-2029) & (USD Million)
Table 91. South America Drugs for Irritable Bowel Syndrome Consumption Value by Country (2018-2023) & (USD Million)
Table 92. South America Drugs for Irritable Bowel Syndrome Consumption Value by Country (2024-2029) & (USD Million)
Table 93. Middle East & Africa Drugs for Irritable Bowel Syndrome Consumption Value by Type (2018-2023) & (USD Million)
Table 94. Middle East & Africa Drugs for Irritable Bowel Syndrome Consumption Value by Type (2024-2029) & (USD Million)
Table 95. Middle East & Africa Drugs for Irritable Bowel Syndrome Consumption Value by Application (2018-2023) & (USD Million)
Table 96. Middle East & Africa Drugs for Irritable Bowel Syndrome Consumption Value by Application (2024-2029) & (USD Million)
Table 97. Middle East & Africa Drugs for Irritable Bowel Syndrome Consumption Value by Country (2018-2023) & (USD Million)
Table 98. Middle East & Africa Drugs for Irritable Bowel Syndrome Consumption Value by Country (2024-2029) & (USD Million)
Table 99. Drugs for Irritable Bowel Syndrome Raw Material
Table 100. Key Suppliers of Drugs for Irritable Bowel Syndrome Raw Materials
LIST OF FIGURES
Figure 1. Drugs for Irritable Bowel Syndrome Picture
Figure 2. Global Drugs for Irritable Bowel Syndrome Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Type in 2022
Figure 4. Alosetron
Figure 5. Lubiprostone
Figure 6. Linaclotide
Figure 7. Others
Figure 8. Global Drugs for Irritable Bowel Syndrome Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 9. Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Application in 2022
Figure 10. Hospital Picture
Figure 11. Clinic Picture
Figure 12. Others Picture
Figure 13. Global Drugs for Irritable Bowel Syndrome Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 14. Global Drugs for Irritable Bowel Syndrome Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 15. Global Market Drugs for Irritable Bowel Syndrome Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 16. Global Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Region (2018-2029)
Figure 17. Global Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Region in 2022
Figure 18. North America Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 20. Asia-Pacific Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 21. South America Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 22. Middle East and Africa Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 23. Global Drugs for Irritable Bowel Syndrome Revenue Share by Players in 2022
Figure 24. Drugs for Irritable Bowel Syndrome Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 25. Global Top 3 Players Drugs for Irritable Bowel Syndrome Market Share in 2022
Figure 26. Global Top 6 Players Drugs for Irritable Bowel Syndrome Market Share in 2022
Figure 27. Global Drugs for Irritable Bowel Syndrome Consumption Value Share by Type (2018-2023)
Figure 28. Global Drugs for Irritable Bowel Syndrome Market Share Forecast by Type (2024-2029)
Figure 29. Global Drugs for Irritable Bowel Syndrome Consumption Value Share by Application (2018-2023)
Figure 30. Global Drugs for Irritable Bowel Syndrome Market Share Forecast by Application (2024-2029)
Figure 31. North America Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Type (2018-2029)
Figure 32. North America Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Application (2018-2029)
Figure 33. North America Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Country (2018-2029)
Figure 34. United States Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 35. Canada Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 36. Mexico Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 37. Europe Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Type (2018-2029)
Figure 38. Europe Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Application (2018-2029)
Figure 39. Europe Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Country (2018-2029)
Figure 40. Germany Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 41. France Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 42. United Kingdom Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 43. Russia Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 44. Italy Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 45. Asia-Pacific Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Type (2018-2029)
Figure 46. Asia-Pacific Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Application (2018-2029)
Figure 47. Asia-Pacific Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Region (2018-2029)
Figure 48. China Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 49. Japan Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 50. South Korea Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 51. India Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 52. Southeast Asia Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 53. Australia Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 54. South America Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Type (2018-2029)
Figure 55. South America Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Application (2018-2029)
Figure 56. South America Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Country (2018-2029)
Figure 57. Brazil Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 58. Argentina Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 59. Middle East and Africa Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Type (2018-2029)
Figure 60. Middle East and Africa Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Application (2018-2029)
Figure 61. Middle East and Africa Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Country (2018-2029)
Figure 62. Turkey Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 63. Saudi Arabia Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 64. UAE Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 65. Drugs for Irritable Bowel Syndrome Market Drivers
Figure 66. Drugs for Irritable Bowel Syndrome Market Restraints
Figure 67. Drugs for Irritable Bowel Syndrome Market Trends
Figure 68. Porters Five Forces Analysis
Figure 69. Manufacturing Cost Structure Analysis of Drugs for Irritable Bowel Syndrome in 2022
Figure 70. Manufacturing Process Analysis of Drugs for Irritable Bowel Syndrome
Figure 71. Drugs for Irritable Bowel Syndrome Industrial Chain
Figure 72. Methodology
Figure 73. Research Process and Data Source
Figure 1. Drugs for Irritable Bowel Syndrome Picture
Figure 2. Global Drugs for Irritable Bowel Syndrome Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Type in 2022
Figure 4. Alosetron
Figure 5. Lubiprostone
Figure 6. Linaclotide
Figure 7. Others
Figure 8. Global Drugs for Irritable Bowel Syndrome Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 9. Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Application in 2022
Figure 10. Hospital Picture
Figure 11. Clinic Picture
Figure 12. Others Picture
Figure 13. Global Drugs for Irritable Bowel Syndrome Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 14. Global Drugs for Irritable Bowel Syndrome Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 15. Global Market Drugs for Irritable Bowel Syndrome Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 16. Global Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Region (2018-2029)
Figure 17. Global Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Region in 2022
Figure 18. North America Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 20. Asia-Pacific Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 21. South America Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 22. Middle East and Africa Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 23. Global Drugs for Irritable Bowel Syndrome Revenue Share by Players in 2022
Figure 24. Drugs for Irritable Bowel Syndrome Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 25. Global Top 3 Players Drugs for Irritable Bowel Syndrome Market Share in 2022
Figure 26. Global Top 6 Players Drugs for Irritable Bowel Syndrome Market Share in 2022
Figure 27. Global Drugs for Irritable Bowel Syndrome Consumption Value Share by Type (2018-2023)
Figure 28. Global Drugs for Irritable Bowel Syndrome Market Share Forecast by Type (2024-2029)
Figure 29. Global Drugs for Irritable Bowel Syndrome Consumption Value Share by Application (2018-2023)
Figure 30. Global Drugs for Irritable Bowel Syndrome Market Share Forecast by Application (2024-2029)
Figure 31. North America Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Type (2018-2029)
Figure 32. North America Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Application (2018-2029)
Figure 33. North America Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Country (2018-2029)
Figure 34. United States Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 35. Canada Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 36. Mexico Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 37. Europe Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Type (2018-2029)
Figure 38. Europe Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Application (2018-2029)
Figure 39. Europe Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Country (2018-2029)
Figure 40. Germany Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 41. France Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 42. United Kingdom Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 43. Russia Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 44. Italy Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 45. Asia-Pacific Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Type (2018-2029)
Figure 46. Asia-Pacific Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Application (2018-2029)
Figure 47. Asia-Pacific Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Region (2018-2029)
Figure 48. China Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 49. Japan Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 50. South Korea Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 51. India Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 52. Southeast Asia Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 53. Australia Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 54. South America Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Type (2018-2029)
Figure 55. South America Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Application (2018-2029)
Figure 56. South America Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Country (2018-2029)
Figure 57. Brazil Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 58. Argentina Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 59. Middle East and Africa Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Type (2018-2029)
Figure 60. Middle East and Africa Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Application (2018-2029)
Figure 61. Middle East and Africa Drugs for Irritable Bowel Syndrome Consumption Value Market Share by Country (2018-2029)
Figure 62. Turkey Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 63. Saudi Arabia Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 64. UAE Drugs for Irritable Bowel Syndrome Consumption Value (2018-2029) & (USD Million)
Figure 65. Drugs for Irritable Bowel Syndrome Market Drivers
Figure 66. Drugs for Irritable Bowel Syndrome Market Restraints
Figure 67. Drugs for Irritable Bowel Syndrome Market Trends
Figure 68. Porters Five Forces Analysis
Figure 69. Manufacturing Cost Structure Analysis of Drugs for Irritable Bowel Syndrome in 2022
Figure 70. Manufacturing Process Analysis of Drugs for Irritable Bowel Syndrome
Figure 71. Drugs for Irritable Bowel Syndrome Industrial Chain
Figure 72. Methodology
Figure 73. Research Process and Data Source
